Management of osteonecrosis of the jaws in patients with history of bisphosphonates therapy

Journal of Craniofacial Surgery

Volumn 21, Issue 6, 2010, Pages 1962-1966

  Antonini, Fernando ^a   Pereira, Cassiano Costa Silva ^b   Parente, Eduardo Varela ^c   Azambuja, Fabiano Goulart ^d  

^a LSUHSC School of Dentistry   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d Private Practice   (Brazil)

Author keywords

bisphosphonates; hyperbaric oxygen therapy; Osteonecrosis; platelet rich plasma

Indexed keywords

ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CEFALEXIN; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

AGED; ARTIFICIAL MEMBRANE; BIODEGRADABLE IMPLANT; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; DEBRIDEMENT; FEMALE; FOLLOW UP; HUMAN; HYPERBARIC OXYGEN; JAW DISEASE; MULTIMODALITY CANCER THERAPY; OSTEOSCLEROSIS; PATIENT CARE; PHYSIOLOGY; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME; WOUND HEALING;

ABSORBABLE IMPLANTS; AGED; ANTI-BACTERIAL AGENTS; BONE DENSITY CONSERVATION AGENTS; CEPHALEXIN; COMBINED MODALITY THERAPY; DEBRIDEMENT; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERBARIC OXYGENATION; IMIDAZOLES; MAXILLARY DISEASES; MEMBRANES, ARTIFICIAL; OSTEONECROSIS; OSTEOSCLEROSIS; PATIENT CARE TEAM; PLATELET-RICH PLASMA; TREATMENT OUTCOME; WOUND HEALING;

EID: 78650563048     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/SCS.0b013e3181f4ee4e     Document Type: Conference Paper

References (29)

1. Cavanna L, Berte R, Arcari A, et al. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Int Med 2007;18:417-422
2. Eckert AW, Maurer P, Meyer L, et al. Bisphosphonate-related jaw necrosis-severe complication in maxillofacial surgery. Cancer Treat Rev 2007;33:58-63
3. Magopoulos C, Karakinaris G, Telioudis Z, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 2007;28:158-163
4. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-631
5. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-923
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1121
7. Ruggiero SL, Mekrota B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-533
8. Montebugnoli L, Felicetti L, Gissi DB, et al. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104: 473-477
9. Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 2006;73:7-9
10. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85
11. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35: 588-593
12. Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423
13. Herbozo PJ, Briones DL, Ferres AJ, et al. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:1650-1654
14. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65: 2397-2410
15. Curi MM, Cossolin GSI, Koga DH, et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007;65:349-355
16. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-1327
17. Santini D, Vicenzi B, Dicuonzo G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-2899
18. Marx RE, Sawatari Y, Fortin M. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63: 1567-1577
19. Adler SC, Kent KJ. Enhancing healing with growth factors. Facial Plast Surg Clin North Am 2002;10:129-138
20. Carlson NE, Roach RB Jr. Platelet rich plasma: clinical applications in dentistry. J Am Dent Assoc 2002;133:1383-1391
21. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-496
22. Curi MM, Dib LL, Kowalski LP. Management of refractory osteoradionecrosis of the jaws with surgery and adjunctive hyperbaric oxygen therapy. Int J Oral Maxillofac Surg 2000;29: 430-434
23. Peleg M, Lopez EA. The treatment of osteoradionecrosis of the mandible: the case for hyperbaric oxygen and bone graft reconstruction. J Oral Maxillofac Surg 2006;64:956-960
24. Diego R, D'orto O, Pagani D, et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:e1-e5
25. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14
26. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonates- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93
27. Schimitz JP, Hollinger JO. The biology of platelet-rich plasma [Letter to the Editor]. J Oral Maxillofac Surg 2001;59:1119
28. Ha H, Kwak HB, Lee SW, et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 2004;301:119-127
29. Thorn JJ, Kallehave F, Westergaard P, et al. The effect of hyperbaric oxygen on irradiated oral tissues: transmucosal oxygen tension measurements. J Oral Maxillofac Surg 1997;55:103-107